Mikhail V. Pletnikov, M.D., Ph.D. is Professor in Department of Psychiatry at Johns Hopkins University School of Medicine. He received his M.D. in 1986 from I.M. Sechenov Moscow Medical Academy, Moscow, Russia and his Ph.D. in Normal Physiology in 1990 from P.K. Anokhin Institute of Normal Physiology, Moscow, Russia. He did his post-doctoral training under Dr Timothy H. Moran (1996-1999) at the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and under Dr Kathryn M. Carbone (1996-1999) at the laboratory of pediatric and respiratory viral infections, the Center for Biologics Evaluation and Research (CBER), the U.S. Food and Drug Administration. He joined faculty in Department of Psychiatry at Johns Hopkins University in 1999. His current research interests focus on understanding pathogenesis of human psychiatric disease with neurodevelopmental origin, e.g., schizophrenia and autism with particular emphasis on a role of gene-environment interactions and the neuro-immune interplay in the complex pathogenesis of psychiatric conditions. Dr Pletnikov is also Director of the Behavioral Core at the School of Medicine. John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.

• Part I: From Clinical Dimensions to Animal ModelsClinical and Pathological Aspects1. Overview of Schizophrenia: Dimensions of Psychopathology2. Overview of Schizophrenia: Epidemiology and PathobiologyAnimal Models of Psychotic Disorders: Dimensional Approach3. Overview of the Dimensional Approach in Basic Research4. Modeling Positive Symptoms 5. Modeling Negative Symptoms6. Modeling Cognitive Impairment7. Modeling Affective SymptomsPart II: Neurobiology of Psychotic DisordersNon-Genetic Models8. MAM-Related Models9. Social Isolation Models10. Pharmacological/Substance Abuse Models 11a. Etiological Environmental Models: Maternal Immune Activation11b. Etiological Environmental Models: Viral Infection Models 11c. Etiological Environmental Models: Stress Models12. Toxoplasma Models 13. Nutritional AlterationsGenetic Models14a. Mouse Models: Risk Genes14b. Mouse Models: CNV Models15. Rat ModelsGene-Gene and Gene-Environment Models16. Gene-Gene Models17. Gene-Environmental Models18. Rodent Models of Multiple Environmental Exposures with Relevance to SchizophreniaCell Models19. Synaptic Abnormalities and Neuroplasticity 20. iPS Models21. Olfactory Epithelium and iN Models  22. Neuron-Glia Interaction Molecular Studies23. Intracellular Signaling24. Hormones25. Oxidative Stress26. Immune Dysregulation; Autoantibodies 27. Future Directions

Mikhail V. Pletnikov, M.D., Ph.D. is Professor in Department of Psychiatry at Johns Hopkins University School of Medicine. He received his M.D. in 1986 from I.M. Sechenov Moscow Medical Academy, Moscow, Russia and his Ph.D. in Normal Physiology in 1990 from P.K. Anokhin Institute of Normal Physiology, Moscow, Russia. He did his post-doctoral training under Dr Timothy H. Moran (1996-1999) at the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and under Dr Kathryn M. Carbone (1996-1999) at the laboratory of pediatric and respiratory viral infections, the Center for Biologics Evaluation and Research (CBER), the U.S. Food and Drug Administration. He joined faculty in Department of Psychiatry at Johns Hopkins University in 1999. His current research interests focus on understanding pathogenesis of human psychiatric disease with neurodevelopmental origin, e.g., schizophrenia and autism with particular emphasis on a role of gene-environment interactions and the neuro-immune interplay in the complex pathogenesis of psychiatric conditions. Dr Pletnikov is also Director of the Behavioral Core at the School of Medicine. John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.

• Part I: From Clinical Dimensions to Animal ModelsClinical and Pathological Aspects1. Overview of Schizophrenia: Dimensions of Psychopathology2. Overview of Schizophrenia: Epidemiology and PathobiologyAnimal Models of Psychotic Disorders: Dimensional Approach3. Overview of the Dimensional Approach in Basic Research4. Modeling Positive Symptoms 5. Modeling Negative Symptoms6. Modeling Cognitive Impairment7. Modeling Affective SymptomsPart II: Neurobiology of Psychotic DisordersNon-Genetic Models8. MAM-Related Models9. Social Isolation Models10. Pharmacological/Substance Abuse Models 11a. Etiological Environmental Models: Maternal Immune Activation11b. Etiological Environmental Models: Viral Infection Models 11c. Etiological Environmental Models: Stress Models12. Toxoplasma Models 13. Nutritional AlterationsGenetic Models14a. Mouse Models: Risk Genes14b. Mouse Models: CNV Models15. Rat ModelsGene-Gene and Gene-Environment Models16. Gene-Gene Models17. Gene-Environmental Models18. Rodent Models of Multiple Environmental Exposures with Relevance to SchizophreniaCell Models19. Synaptic Abnormalities and Neuroplasticity 20. iPS Models21. Olfactory Epithelium and iN Models  22. Neuron-Glia Interaction Molecular Studies23. Intracellular Signaling24. Hormones25. Oxidative Stress26. Immune Dysregulation; Autoantibodies 27. Future Directions

Mikhail V. Pletnikov, M.D., Ph.D. is Professor in Department of Psychiatry at Johns Hopkins University School of Medicine. He received his M.D. in 1986 from I.M. Sechenov Moscow Medical Academy, Moscow, Russia and his Ph.D. in Normal Physiology in 1990 from P.K. Anokhin Institute of Normal Physiology, Moscow, Russia. He did his post-doctoral training under Dr Timothy H. Moran (1996-1999) at the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and under Dr Kathryn M. Carbone (1996-1999) at the laboratory of pediatric and respiratory viral infections, the Center for Biologics Evaluation and Research (CBER), the U.S. Food and Drug Administration. He joined faculty in Department of Psychiatry at Johns Hopkins University in 1999. His current research interests focus on understanding pathogenesis of human psychiatric disease with neurodevelopmental origin, e.g., schizophrenia and autism with particular emphasis on a role of gene-environment interactions and the neuro-immune interplay in the complex pathogenesis of psychiatric conditions. Dr Pletnikov is also Director of the Behavioral Core at the School of Medicine. John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.John Waddington is currently Professor of Neuroscience in Molecular and Cellular Therapeutics at the Royal College of Surgeons in Ireland (RCSI), Dublin. He received a BA in Natural Sciences from the University of Cambridge, and a PhD in Neuropharmacology followed by a DSc in Neuroscience from the University of London. After working with the UK Medical Research Council in the Division of Psychiatry at their Clinical Research Centre, he joined RCSI and became Chairman of Clinical Pharmacology in 2004. In 2003, he became the first person from RCSI to be elected to membership of the Royal Irish Academy; he has received the Lilly Neuroscience Award from the International College of Neuropsychopharmacology and the Award for Outstanding Achievement in Basic Science from the Schizophrenia International Research Society. His research is focused on the pathobiology and psychopharmacology of psychotic illness, mutant models of schizophrenia and other psychoses, and the pathobiology, psychopharmacology and mutant modelling of movement disorder.

• Part I: From Clinical Dimensions to Animal ModelsClinical and Pathological Aspects1. Overview of Schizophrenia: Dimensions of Psychopathology2. Overview of Schizophrenia: Epidemiology and PathobiologyAnimal Models of Psychotic Disorders: Dimensional Approach3. Overview of the Dimensional Approach in Basic Research4. Modeling Positive Symptoms 5. Modeling Negative Symptoms6. Modeling Cognitive Impairment7. Modeling Affective SymptomsPart II: Neurobiology of Psychotic DisordersNon-Genetic Models8. MAM-Related Models9. Social Isolation Models10. Pharmacological/Substance Abuse Models 11a. Etiological Environmental Models: Maternal Immune Activation11b. Etiological Environmental Models: Viral Infection Models 11c. Etiological Environmental Models: Stress Models12. Toxoplasma Models 13. Nutritional AlterationsGenetic Models14a. Mouse Models: Risk Genes14b. Mouse Models: CNV Models15. Rat ModelsGene-Gene and Gene-Environment Models16. Gene-Gene Models17. Gene-Environmental Models18. Rodent Models of Multiple Environmental Exposures with Relevance to SchizophreniaCell Models19. Synaptic Abnormalities and Neuroplasticity 20. iPS Models21. Olfactory Epithelium and iN Models  22. Neuron-Glia Interaction Molecular Studies23. Intracellular Signaling24. Hormones25. Oxidative Stress26. Immune Dysregulation; Autoantibodies 27. Future Directions